Kistler-Tiffany Companies’s Repros Therapeutics Inc. RPRX Stock Holding History

Kistler-Tiffany Companies’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-270	Closed	-$1K	–	580
2016 Q3	$1K	Hold	270	–	–	﹤0.01%	552
2016 Q2	$0	Hold	270	–	–	﹤0.01%	788
2016 Q1	$0	Hold	270	–	–	﹤0.01%	625
2015 Q4	$0	Hold	270	–	–	﹤0.01%	659
2015 Q3	$2K	Hold	270	–	–	﹤0.01%	562
2015 Q2	$2K	Hold	270	–	–	﹤0.01%	571
2015 Q1	$2K	Hold	270	–	–	﹤0.01%	547
2014 Q4	$3K	Hold	270	–	–	﹤0.01%	531
2014 Q3	$3K	Hold	270	–	–	﹤0.01%	546
2014 Q2	$5K	Hold	270	–	–	﹤0.01%	504
2014 Q1	$5K	Hold	270	–	–	﹤0.01%	493
2013 Q4	$5K	Hold	270	–	–	﹤0.01%	499
2013 Q3	$7K	Hold	270	–	–	0.01%	470
2013 Q2	$5K	Buy	+270	New	+$4.77K	﹤0.01%	498

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Kistler-Tiffany Companies's RPRX Position: Q4 2016 in Review

Kistler-Tiffany Companies sold out of Repros Therapeutics Inc. (RPRX) in Q4 2016, closing a stake of 270 shares — an estimated $1K sold.

Kistler-Tiffany Companies first reported a position in RPRX in Q2 2013 and held it in 14 quarters. The position peaked at $7K in Q3 2013. 43 funds tracked by Wall St. Rank hold RPRX as of Q4 2016.

Kistler-Tiffany Companies reported no remaining Repros Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
Kistler-Tiffany Companies sold 270 Repros Therapeutics Inc. shares in Q4 2016, an estimated $1K.
Kistler-Tiffany Companies first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 14 quarters.
Kistler-Tiffany Companies's Repros Therapeutics Inc. position peaked at $7K in Q3 2013.
43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2016.

Based on Kistler-Tiffany Companies's 13F filing for Q4 2016, filed 3 Feb 2017.